ORI Capital’s 2.8x return on its investment in Kymab was in part based on helping the company make the transition from antibody-based discovery platform to drug development engine
Simone Song’s deal sourcing network is professional and personal. The Goldman Sachs investment banker-turned-healthcare venture capital investor first learned about UK biotech specialist Kymab from one...
SciClone Pharmaceuticals, a Chinese drug developer privatized by a PE consortium at a valuation of $605 million in 2017, has relisted in Hong Kong and ended its first day of trading with a market capitalization of HK$12.7 billion ($1.64 billion).
Iluvatar CoreX, a Shanghai-based computing chip designer has raised RMB1.2 billion ($186 million) in Series C funding led by Cedarlake Capital and Centurium Capital.
China’s less-than-truckload logistics market, which sits in between express couriers and big truck operators, is ripe for consolidation. GPs have identified their favored players
US-based Platinum Equity has exited its control position in Sensis, best known as the operator of Australia’s White Pages and Yellow Pages directories, in a deal worth $200 million.